{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T04:31:05Z","timestamp":1766032265419,"version":"3.48.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ibroneuroreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IBRO Neuroscience Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ibneur.2025.08.015","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:37:23Z","timestamp":1760809043000},"page":"981-987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Assessment of differences in clinical consequences between rituximab and interferon recipients in multiple sclerosis patients after recovery from COVID-19"],"prefix":"10.1016","volume":"19","author":[{"given":"Arash","family":"Musa AL-Rezai Aghdam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayan","family":"Sarkhosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Farrokhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-6914","authenticated-orcid":false,"given":"Saleh","family":"Behzadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazanin","family":"Moeini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Mehranfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ibneur.2025.08.015_bib1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10096-020-03874-z","article-title":"The epidemiology and clinical information about COVID-19","volume":"39","author":"Ge","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"issue":"10224","key":"10.1016\/j.ibneur.2025.08.015_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet (Lond. Engl. )"},{"issue":"2","key":"10.1016\/j.ibneur.2025.08.015_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000862","article-title":"SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity","volume":"8","author":"Wei","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.ibneur.2025.08.015_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ana.25907","article-title":"Multiple sclerosis Disease-Modifying therapies in the COVID-19 era","volume":"88","author":"Ciotti","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ibneur.2025.08.015_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102420","article-title":"Infections in patients with multiple sclerosis: a national cohort study in Sweden","volume":"45","author":"Castelo-Branco","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ibneur.2025.08.015_bib6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0961203313493032","article-title":"Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies","volume":"22","author":"Danza","year":"2013","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.ibneur.2025.08.015_bib7","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.ibneur.2025.08.015_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a north American registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.ibneur.2025.08.015_bib9","article-title":"Incidence and impact of COVID-19 in MS: a survey from a barcelona MS unit","volume":"8","author":"Sep\u00falveda","year":"2021","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.ibneur.2025.08.015_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.ibneur.2025.08.015_bib11","article-title":"Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis","volume":"56","author":"Freedman","year":"2021"},{"issue":"4","key":"10.1016\/j.ibneur.2025.08.015_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.ibneur.2025.08.015_bib13","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult. Scler. (Houndmills Basingstoke Engl. )"},{"unstructured":"Federation M.I. Global COVID-19 advice for people with MS 2020 [updated 21 Oct 2020. Available from: \u3008https:\/\/www.msif.org\/wp-content\/uploads\/2020\/03\/MSIF-Global-advice-on-COVID-19-for-people-with-MS.docx-1.pdf\u3009.","key":"10.1016\/j.ibneur.2025.08.015_bib14"},{"issue":"201","key":"10.1016\/j.ibneur.2025.08.015_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ane.12835","article-title":"Infections in patients with multiple sclerosis: implications for disease-modifying therapy","volume":"136","author":"Celius","year":"2017","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.ibneur.2025.08.015_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.ibneur.2025.08.015_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","article-title":"Infection risk in patients on multiple sclerosis therapeutics","volume":"29","author":"Williamson","year":"2015","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.ibneur.2025.08.015_bib18","first-page":"10115","article-title":"Immunomodulatory role of interferons in viral and bacterial infections","volume":"24","author":"Mertowska","year":"2023"},{"issue":"9","key":"10.1016\/j.ibneur.2025.08.015_bib19","article-title":"Interferon-stimulated genes and their antiviral activity against SARS-CoV-2","volume":"15","author":"Ortega-Prieto","year":"2024"},{"key":"10.1016\/j.ibneur.2025.08.015_bib20","first-page":"2023","article-title":"Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection","volume":"14","author":"Mihaescu","year":"2024"},{"issue":"6","key":"10.1016\/j.ibneur.2025.08.015_bib21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/toxins6061696","article-title":"Type I interferons as regulators of human antigen presenting cell functions","volume":"6","author":"Gessani","year":"2014","journal-title":"Toxins"},{"issue":"5","key":"10.1016\/j.ibneur.2025.08.015_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41590-019-0345-x","article-title":"Interferon-\u03bb enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin","volume":"20","author":"Ye","year":"2019","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.ibneur.2025.08.015_bib23","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ccell.2021.08.005","article-title":"Activating a collaborative innate-adaptive immune response to control metastasis","volume":"39","author":"Sun","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ibneur.2025.08.015_bib24","first-page":"2022","article-title":"Single-cell multiomics revealed the dynamics of antigen presentation, immune response and t cell activation in the COVID-19 positive and recovered individuals","volume":"13","author":"Chattopadhyay","year":"2022"},{"key":"10.1016\/j.ibneur.2025.08.015_bib25","article-title":"Anatomy and physiology 2e","author":"J. Gordon Betts","year":"2022","journal-title":"Houst. Texas2022"},{"issue":"9","key":"10.1016\/j.ibneur.2025.08.015_bib26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"19","key":"10.1016\/j.ibneur.2025.08.015_bib27","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of Disease-Modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ibneur.2025.08.015_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in b Cell-Depleted patients after rituximab: a diagnostic and therapeutic challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ibneur.2025.08.015_bib29","article-title":"Evaluation of the level of anxiety among Iranian multiple sclerosis fellowships during the outbreak of COVID-19","volume":"23","author":"Moghadasi","year":"2020","journal-title":"Arch. Iran. Med. (AIM)"},{"issue":"11","key":"10.1016\/j.ibneur.2025.08.015_bib30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.ibneur.2025.08.015_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ibneur.2025.08.015_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103358","article-title":"Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis","volume":"57","author":"Schiavetti","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.ibneur.2025.08.015_bib33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/13524585211026272","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry","volume":"28","author":"Spelman","year":"2022","journal-title":"Mult. Scler. (Houndmills Basingstoke Engl. )"},{"doi-asserted-by":"crossref","unstructured":"Iyer R.B., S R., M J., R J.J.M.S., Disorders R. COVID-19 outcomes in persons with multiple sclerosis treated with rituximab. 2021;57:103371 -.","key":"10.1016\/j.ibneur.2025.08.015_bib34","DOI":"10.1016\/j.msard.2021.103371"},{"issue":"5","key":"10.1016\/j.ibneur.2025.08.015_bib35","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020"},{"issue":"2","key":"10.1016\/j.ibneur.2025.08.015_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13760-023-02421-9","article-title":"Potential beneficial effect of IFN-\u03b21a and ocrelizumab in people with MS during the COVID-19 pandemic","volume":"124","author":"Todorovi\u0107","year":"2024","journal-title":"Acta Neurol. Belg."},{"issue":"4","key":"10.1016\/j.ibneur.2025.08.015_bib37","article-title":"COVID-19 among patients with multiple sclerosis: a systematic review","volume":"8","author":"Barzegar","year":"2021","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ibneur.2025.08.015_bib38","article-title":"Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles","volume":"14","author":"Fong","year":"2023","journal-title":"Front. Neurol."},{"issue":"15","key":"10.1016\/j.ibneur.2025.08.015_bib39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2020.17052","article-title":"Cytokine levels in critically ill patients with COVID-19 and other conditions","volume":"324","author":"Kox","year":"2020","journal-title":"Jama"},{"doi-asserted-by":"crossref","unstructured":"Wang J., Yang X., Li Y., Huang J.-A., Jiang J., Su N. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction. Virol J [Internet]. 2021 2021\/06\/\/; 18(1):[117 p.]. Available from: \u3008http:\/\/europepmc.org\/abstract\/MED\/34088317\u3009 \u3008https:\/\/virologyj.biomedcentral.com\/counter\/pdf\/10.1186\/s12985-021-01588-y\u3009 https:\/\/doi.org\/10.1186\/s12985-021-01588-y \u3008https:\/\/europepmc.org\/articles\/PMC8177255\u3009 \u3008https:\/\/europepmc.org\/articles\/PMC8177255?pdf=render\u3009.","key":"10.1016\/j.ibneur.2025.08.015_bib40","DOI":"10.1186\/s12985-021-01588-y"},{"issue":"1","key":"10.1016\/j.ibneur.2025.08.015_bib41","doi-asserted-by":"crossref","first-page":"2033540","DOI":"10.1080\/21645515.2022.2033540","article-title":"Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse","volume":"18","author":"Etemadifar","year":"2022","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["IBRO Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242125001319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242125001319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T04:25:19Z","timestamp":1766031919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667242125001319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S2667242125001319"],"URL":"https:\/\/doi.org\/10.1016\/j.ibneur.2025.08.015","relation":{},"ISSN":["2667-2421"],"issn-type":[{"type":"print","value":"2667-2421"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of differences in clinical consequences between rituximab and interferon recipients in multiple sclerosis patients after recovery from COVID-19","name":"articletitle","label":"Article Title"},{"value":"IBRO Neuroscience Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ibneur.2025.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Brain Research Organization.","name":"copyright","label":"Copyright"}]}}